0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Review Article |

Systematic Overview of Warfarin and Its Drug and Food Interactions FREE

Anne M. Holbrook, MD, PharmD, MSc, FRCPC; Jennifer A. Pereira, MSc; Renee Labiris, PhD; Heather McDonald, MSc; James D. Douketis, MD, FRCPC; Mark Crowther, MD, MSc, FRCPC; Philip S. Wells, MD, FRCPC
[+] Author Affiliations

Author Affiliations: Centre for Evaluation of Medicines, St Joseph’s Healthcare, Hamilton, Ontario (Drs Holbrook and Labiris and Ms Pereira); Department of Medicine, McMaster University, Hamilton (Drs Holbrook, Labiris, Douketis, and Crowther); Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario (Dr Holbrook and Ms Pereira); Axon Clinical Research, Toronto (Ms McDonald) and Ottawa Civic Hospital Research Centre, Ottawa, Ontario (Dr Wells).


Arch Intern Med. 2005;165(10):1095-1106. doi:10.1001/archinte.165.10.1095.
Text Size: A A A
Published online

Background  Warfarin is a highly efficacious oral anticoagulant, but its use is limited by a well-founded fear of bleeding. Drug and food interactions are frequently cited as causes of adverse events with warfarin. We provide an updated systematic overview of the quality, clinical effect, and importance of these reported interactions.

Data Sources  MEDLINE, TOXLINE, IPA, and EMBASE databases from October 1993 to March 2004. Database searches combined the keyword warfarin with drug interactions, herbal medicines, Chinese herbal drugs, and food-drug interactions.

Study Selection  Eligible articles contained original reports of warfarin drug or food interactions in human subjects. Non-English articles were included if sufficient information could be abstracted.

Data Extraction  Reports were rated independently by 2 investigators for interaction direction, clinical severity, and quality of evidence. Quality of evidence was based on previously validated causation criteria and study design.

Data Synthesis  Of 642 citations retrieved, 181 eligible articles contained original reports on 120 drugs or foods. Inter-rater agreement was excellent, with weighted κ values of 0.84 to 1.00. Of all reports, 72% described a potentiation of warfarin’s effect and 84% were of poor quality, 86% of which were single case reports. The 31 incidents of clinically significant bleeding were all single case reports. Newly reported interactions included celecoxib, rofecoxib, and herbal substances, such as green tea and danshen.

Conclusions  The number of drugs reported to interact with warfarin continues to expand. While most reports are of poor quality and present potentially misleading conclusions, the consistency of reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil, suggests that coadministration with warfarin should be avoided or closely monitored. More systematic study of warfarin drug interactions in patients is urgently needed.

Warfarin is the most commonly used oral anticoagulant in North America and has established efficacy for the prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease.14 The drug is a racemic mixture of 2 optically active isomers, though the S-enantiomer is approximately 5 times more potent than the R-enantiomer. Warfarin exerts its effect by lowering the amount of active vitamin K available for the activation of clotting factors II, VII, IX, and X.5 Both effectiveness and safety (primarily risk of bleeding) are related to blood international normalized ratio (INR) values. Monitoring of INR and dose adjustments of warfarin are frequently required, influenced by changes in concomitant medications, diet, alcohol consumption, acute illness, liver disease, and unknown factors.5

Despite the frequency and importance of warfarin’s drug and food interactions, the first systematic overview on the topic did not appear until 1994.6 For that review, we developed an interaction assessment tool that combined a “levels of evidence” approach with causation criteria, subject outcome, and proposed mechanisms. Although many drugs, including antibiotics, drugs affecting the central nervous system, and cardiac medications, had been reported to interact with warfarin, the quality of reports was so poor that few clinical recommendations could be made other than careful monitoring around initiating and discontinuing treatment with other medications. In the decade since that review, awareness and investigation of drug interactions and quality of evidence have grown, leading to the hypothesis that the number and quality of drug and food interactions would increase as well. We therefore performed a systematic overview of the literature, updating the evidence on warfarin drug and food interactions.

Relevant literature was identified by searching MEDLINE, TOXLINE, IPA, EMBASE databases, Health Canada and Food and Drug Administration Web sites and personal files from October 1993 to the end of March 2004. The MeSH headings and keywords used for the search were warfarin and drug interactions. Non-English articles were included if they included an English abstract with sufficient information. To retrieve warfarin-herbal drug interactions and warfarin-food interactions, 2 additional searches were conducted using the MeSH headings and keywords warfarin and herbal medicines or Chinese herbal drugs, and MeSH headings food-drug interactions and warfarin, limited to English only. The bibliographies of the retrieved articles were checked for any additional pertinent studies. Articles were considered eligible for evaluation if they contained original data involving drug or food interactions with warfarin in human subjects. Interacting drugs had to be available in the United States or Canada. Eligible studies were evaluated independently by 2 authors according to the following 4 main categories.

SUBJECT

Subjects were classified as patients or healthy volunteers. Patients were then further stratified into 2 categories: volunteers and nonvolunteers. The former group were defined as patients requiring warfarin therapy who were prospectively entered into a study, whereas the latter group was exposed to the interacting drug during the course of usual warfarin therapy. Healthy volunteers were healthy individuals not requiring warfarin therapy.

INTERACTION CLASSIFICATION AND SEVERITY

The drug affected and the type of interaction (potentiation, inhibition, or no effect) were noted. Interactions that potentiated or inhibited the effect of warfarin were further rated as major, moderate, minor, or nonclinical.

Major potentiation was defined by death, major bleeding, or necessity to stop warfarin therapy entirely. Major bleeding episodes included those that were life-threatening as well as those that led to the loss of at least 2 units of blood in 7 days or less.7 Moderate potentiation meant that (1) there was an INR change requiring an adjustment in warfarin dosage or (2) the INR increased to greater than 5.0 or (3) there was an increase in INR by greater than 1.5. Minor potentiation interactions were defined as an INR increase in which (1) no change in warfarin dosage was required and (2) the ratio remained less than 5 and (3) the increase was less than 1.5. Potentiation interactions were classified as nonclinical if the only evidence of warfarin augmentation was a statistically significant increase in warfarin levels without change in INR or clinical status.

Major inhibition interactions were defined by the occurrence of thrombosis. Moderate inhibition (clinically relevant but less than major) indicated (1) a change in INR requiring an adjustment in warfarin dosage or (2) an INR decrease to less than 1.5 or (3) a decrease in INR by greater than 1.5 units. Minor inhibition interactions were defined by (1) an INR decrease requiring no change in warfarin dosage and (2) an INR decrease to a ratio that remained more than 1.5 and (3) a decrease in INR by less than 1.5. Inhibition interactions were classified as nonclinical if the only evidence of warfarin inhibition was a statistically significant decrease in warfarin levels.

An interaction was defined as having no effect if the interacting drug neither potentiated nor inhibited warfarin’s effect in any way described herein.

QUALITY OF STUDY

Reports were classified into 1 of 4 categories based on the quality of study design. As shown in Table 1, randomized controlled trials (RCTs) were subdivided into fair to excellent quality, with those involving more than 100 subjects arbitrarily given the highest rating. Poor quality reports included nonrandomized study designs, observational studies, pharmacokinetic studies, and case reports.

CAUSATION CRITERIA

For each report, the probability of the proposed interaction was rated from level I (highly probable) to level IV (highly improbable). Definitive evidence of an interaction required a level I causation rating from both healthy volunteer and patient-based reports in which both described identical interaction direction and severity. Level designation was based on how the article fulfilled 7 standard causation criteria.

  • Is the timing correct for an interaction to be pharmacologically plausible? In patient-based studies, warfarin must have been taken at a stabilized dose common to usual practice and prior to initiation of the interacting drug or food. For volunteer-based studies, subjects had to have received warfarin, both alone as well as with the interacting drug. In addition, we required that the potentially interacting drug had to be consumed (1) long enough to attain a significant plasma level and (2) in doses common to usual practice.

  • Do laboratory tests (eg, international normalized ratio/prothrombin time/thrombotest) support the contention of an interaction? In patient-based articles, the post-coadministration coagulation variable had to be out of therapeutic range, whereas for volunteer studies, a 20% change in coagulation parameters for volunteer studies was required. For articles concluding “no interaction,” the absence of a statistically significant change in coagulation variables was required.

  • Are other potential factors affecting warfarin pharmacokinetics/pharmacodynamics ruled out satisfactorily? Factors such as diet, other medications, as well as certain medical conditions (hepatic dysfunction and hyperthyroidism) had to have been declared to be ruled out as possible causes of the outcome.

  • Has the patient had a similar result with previous exposure to the same drug? The patient had to have been taking the interacting drug in addition to warfarin at a time prior to that reported with a similar outcome.

  • Was a dose-response relationship demonstrated for the interacting drug? The alterations in the dose of the implicated interacting drug or food being administered with warfarin correlated with subsequent changes in coagulation variables, inferring a dose-response relationship.

  • Was the subject rechallenged and, if so, did a similar response occur? The interacting drug had to have been administered simultaneously with warfarin in 2 or more separate courses (the second course conducted to confirm the results of the first), with similar results each time.

  • Are the authors’ conclusions supported by other objective evidence? Other objective evidence such as plasma levels of warfarin or coagulation factors supported the authors’ conclusions.

RELIABILITY AND VALIDITY

The criteria and rating scheme were evaluated and approved a priori by a panel of experts in the fields of thromboembolism, clinical pharmacology, and clinical epidemiology to assure face validity. Interrater agreement for interaction direction and severity, quality of study, and level of causation was assessed using a weighted κ statistic.8

CONFLICTING EVIDENCE

If ratings differed among articles for the same interacting drug or food, a hierarchy was implemented (type of subject > quality of study > level of causation > severity of clinical outcome). For example, a case report involving a patient was considered to be superior to an RCT using healthy volunteers as subjects. If 2 or more articles had the same subject type, the result of the highest quality study was listed—a patient-based RCT was considered superior to a patient case report. If 2 or more articles with the same subject type and quality of study varied in level of causation and clinical outcome, the clinical outcome associated with the highest level of evidence was listed. For example, the case report describing moderate potentiation of warfarin by celecoxib, with a level II causation rating9 outweighed the level III case report describing a similar interaction.10 For 2 level III causation patient case reports describing amoxicillin’s effect on warfarin, the report describing major potentiation11 outweighed the one describing moderate potentiation.11

A total of 642 citations were identified, of which 205 contained original data on drug or food interactions with warfarin. Of these 205 articles, 181 were retrievable and available for review. The reviewed articles contained 187 separate reports of interactions involving 120 drugs or foods. The weighted κ statistic for the interaction direction and severity rating, level of causation evaluation, and quality of study rating among the reviewers were 0.98, 0.84, and 1.0 respectively. All rating disagreements were resolved by repeated review and consensus.

No study met our definition of excellent quality. Thirty-three small RCTs were rated fair or good quality, of which 28 involved healthy subjects and 26 concluded a lack of interaction between warfarin and the drug or food studied. Olestra,12 vitamin E,13 clopidogrel,14 coenzyme Q10/ginkgo biloba 10,15 and ciprofloxacin16 were the only drugs for which patient-based RCTs were conducted, with a “no effect” conclusion for olestra, vitamin E, clopidogrel, and coenzyme Q10/gingko biloba and nonclinical potentiation for ciprofloxacin. Of the reviewed studies, 148 (82%) were rated poor quality and 130 (88%) of these were case reports, of which 125 (96%) were single case reports.

Forty-one new reports were rated as level I causation (highly probable) for an interaction, with 14 reporting potentiation (acetaminophen,17 boldo-fenugreek,18 ciprofloxacin,16 citalopram,19 diltiazem,20 entacapone,21 fenofibrate,22 fish oil,23 mango,24 miconazole vaginal suppositories,25 quilinggao,26 sertraline,27 voriconazole,28 and zileuton29), 5 reporting inhibition (etodolac,30 mercaptopurine,31 mesalamine,32 ribavirin,33 and trazodone34), and 22 reporting “no effect” (anastrozole,35 argatroban,36 cilostazol,37 clopidogrel,14 donepezil hydrochloride,38 eprosartan,39 entacapone,40 gemifloxacin,41 levetiracetam,42 losartan,43 meloxicam,44 metrifonate,45 miglitol,46 modafinil,47 moexipril,48 montelukast,49 nateglinide,50 nefazodone,51 olestra,12 pantoprazole,52 sevelamer hydrochloride,53 and vitamin E13).

For 38 drugs or foods, level II causation (probable) criteria were met, and for the remaining 41 drugs or foods, the evidence was even less conclusive. Only 57 (31%) of the studies ruled out potential confounders, and fewer than 20% of the articles provided rechallenge data, demonstration of a dose response relationship, or a description of a previous exposure in which the patient experienced a similar effect.

Of all 184 reviewed reports, 128 (70%) described a potentiation of warfarin’s effect, while inhibition and “no effect” reports each comprised 28 (15%). There were 34 reports of a major interaction—3 case reports of thrombosis associated with trazodone, sulfasalazine, and propofol and 31 case reports describing a major potentiation. These included 8 deaths, 4 of which were due to intracranial bleeding associated with celecoxib, ciprofloxacin, and fluoxetine/diazepam coadministration.5456 Only 2 of all 34 reports were level I, describing inhibition involving mesalamine and trazodone.32,34 Several herbal drugs, foods rich in vitamin K, and carbamazepine were reported to decrease warfarin’s effect as were other anti-infective agents, including griseofulvin, rifampin, and penicillinase-resistant penicillins, such as nafcillin, dicloxacillin, and cloxacillin.

There were 3 drugs—terbinafine, ritonavir, and influenza vaccine—for which conflicting evidence of an interaction with warfarin was presented.5763 A cumulative summary, combining evaluations from our original review6 with those of the update is presented in Table 2. Although few interactions met level I causation requirements, the recurrent reports on nonsteroidal anti-inflammatory drugs (NSAIDs),230 antibiotics (particularly macrolides—azithromycin,124 erythromycin,11 and clarithromycin126), azoles (fluconazole231 and miconazole25), amoxicillin, and quinolones (ciprofloxacin16 and levofloxacin139) continue. New alerts regarding the potential for major bleeding when warfarin is taken with cyclooxygenase-2 (COX-2) selective NSAIDs9,10,55,232 or herbal drugs are raised.127,233Table 3 presents a summary of all clinically significant potentiation and inhibition interactions with warfarin, based on drug family and level of causation.

Table Graphic Jump LocationTable 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction*
Table Graphic Jump LocationTable 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug Group

The most commonly cited mechanisms for interactions with warfarin involved stereoselective clearance due to S-enantiomer (ritonavir and cotrimoxazole) or nonstereoselective clearance (simvastatin and terbinafine) or the vitamin K pathway (green tea). However, most of the interactions reported have no documented mechanism.

This updated review indicates that the number of reports of interactions between warfarin and drugs or foods is increasing, reaffirming both the anticoagulant’s widespread use and its use with concomitant medications. Although the true mechanisms of drug interactions almost always remain unknown, there are several pharmacokinetic and pharmacodynamic factors that could influence warfarin’s effect. Cholestyramine is thought to reduce the gastrointestinal absorption of warfarin.97,234 The more potent warfarin S-isomer is metabolized by cytochrome P-450 (CYP) 2C9. Many of the drugs identified as potentiating warfarin’s effect are known inhibitors of CYP 2C9, including amiodarone, fluconazole, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, and sertraline.235 Rifampin and secobarbital are both known inducers of CYP 2C9.93,102 The R-isomer of warfarin is metabolized by CYP 1A2 and CYP 3A4, and quinolones16,139 inhibit CYP 1A2, and macrolides11,124,126 inhibit CYP 3A4. The azoles (several reports involving metronidazole, fluconazole, trimethoprim-sulfamethoxazole, miconazole, and voriconazole25,28,79,8183,236) are also considered to inhibit CYP 1A2 or CYP 3A4. The pharmacodynamics of warfarin may be influenced by medications that affect either vitamin K or the coagulation factors.237 Sudden changes in dietary sources of vitamin K such as leafy greens or a supplemented diet followed by a change in warfarin’s effect are relatively easy to understand.106,238240 However, for several drugs, including cephalosporins, levothyroxine, and clofibrate, their supposed pharmacodynamic interactions with warfarin are very poorly understood.76,214,241

Although understanding a drug’s pharmacology helps predict its potential for interaction with warfarin, the translation of these predictions into clinical reality is far from certain. We also found no evidence that specific factors might identify patient subgroups most at risk of pharmacokinetic drug interactions. Regular monitoring of INR remains the best protection against major harm due to these pharmacokinetic and pharmacodynamic interactions.

The most difficult groups of drugs to deal with are those that potentiate bleeding on their own. The risk of bleeding is then greater when taken with warfarin, and INR monitoring is of no help. This is an issue with other anticoagulants (such as heparin), antiplatelet drugs (eg, acetylsalicylic acid, clopidogrel, dipyridamole, sulfinpyrazone, and ticlopidine) and all NSAIDs including COX-2 selective NSAIDs. All of these drugs should be avoided in combination with warfarin unless proven to provide benefit that outweighs the risk of bleeding—for example, for artificial heart valves.237 Contrary to the early theories of safety of COX-2 selective NSAIDs, we do not consider them safe in combination with warfarin. Both celecoxib (10 cases moderate9,232 to major9,10) and rofecoxib (2 cases moderate9) are reported to potentiate anticoagulation. Acetaminophen, which is the analgesic of choice for patients using warfarin, has case reports17,242 as well as a case-control study243 suggesting moderate potentiation (perhaps based on mild factor VII depletion17,243), although findings from an RCT in healthy volunteers were negative.244

The paradox noted in our original review continues, in that higher-quality studies describe minor or no interaction, while clinically important potentiation or inhibition interactions all originate from poor-quality reports. The overall quality of the interaction literature remains extremely poor, precluding definitive recommendations regarding the safe coadministration or avoidance of specific drugs and foods in users of warfarin. Case reports may be alarming, but their rarity and the lack of a control group, a denominator of use, or often even basic descriptive details makes it impossible to gauge their true accuracy or rate of harm. Small RCTs of new drugs given with warfarin are increasingly common as a result of demands of regulators. These studies, which are invariably carried out with healthy young male volunteers, are too small to provide any assurance of lack of interaction and are likely not generalizable to the usual warfarin consumer—an elderly person with active medical conditions using several other medications. Only 5 of 34 RCTs evaluated in this review involved sample sizes from 24 to 43 patients.1216 Poor-quality literature is not merely an aggravation to review. Twenty of the interaction reports received a level IV causation rating, implying that the interaction was highly improbable based on the lack of fulfillment of basic causation criteria.56,213229 The publication of such reports is potentially harmful itself because it may generate unwarranted concern and erroneously influence prescribing. We were surprised to find no analyses of linked, large administrative databases examining drug interactions with warfarin.

This review has several limitations. Our literature search did not solicit all unpublished adverse interactions reported to drug manufacturers or governments. However, both Health Canada’s Canadian Adverse Drug Reaction Monitoring Program and Food and Drug Administration’s MedWatch were solicited for cases. We also were unable to review all non-English publications. The handling of conflicting evidence, while sensible, could have led to a mistaken conclusion. Others may not agree with our multidimensional, hierarchical evaluation methods.

In the extreme, no drug can be deemed “safe” based on our summary chart because the absence of proof of a severe interaction does not mean proof of absence. Idiosyncratic reactions can always be expected. We therefore continue to recommend careful monitoring of warfarin therapy at the time of introduction of any new medication, herbal product, or food. Herbal products are particularly problematic given the lack of quality control on their contents and the failure of clinicians to ask about their use.245,246

How can clinicians use this information? To prescribe safely, there are 3 choices: one is to never prescribe or allow another medicine to be given with warfarin. This is clearly impractical for most patients requiring warfarin. The second is to use an electronic medical record or prescribing system that will evaluate interactions among the patient’s entire profile of therapies.247,248 Because these systems are not available to most physicians and are frequently incomplete and sometimes inaccurate, a third approach is required. The third option is to group the majority of offending interacting drugs into easier-to-remember families or therapeutic groups, as we have done in Table 3. We recommend to exercise caution when adding any antibiotic to warfarin therapy, especially for macrolides, quinolones, and “azoles.” Many common cardiovascular drugs, including statins, fibrates, heparin, aspirin, and amiodarone, are problematic. Also, NSAIDs, including COX-2 selective NSAIDs, should be avoided, as should omeprazole, alcohol, chloral hydrate, anabolic steroids, and a wide variety of, if not all, herbal supplements. New oral anticoagulants may soon be available but have not demonstrated superior long-term efficacy, safety, or drug interaction profile compared with warfarin.

In summary, there is an abundance of medications and foods for which an adverse interaction with warfarin, generally potentiation of warfarin’s effect, has been reported. While the drug interaction literature is generally of poor quality, relatively consistent reporting of interactions between warfarin and certain commonly used drugs and drug families (mainly anti-infective agents, lipid-lowering drugs, NSAIDs including COX-2 selective NSAIDs, selective serotonin reuptake inhibitors, amiodarone, omeprazole, fluorouracil, and cimetidine) is cause for concern. In patients who are starting therapy with one of these medicines, consideration should be given to using an alternative medication with less potential for warfarin interactions (eg, rabeprazole instead of omeprazole and acetaminophen instead of NSAIDs). More frequent INR testing during the 2 weeks of the onset or discontinuation of treatment with other medications is advisable. Finally, we recommend the use of more rigorous methods to examine warfarin interactions in patients (eg, RCTs, N of 1 crossover studies, or large health database analyses).

Correspondence: Anne M. Holbrook, MD, PharmD, MSc, FRCPC, Division of Clinical Pharmacology, McMaster University, c/o Centre for Evaluation of Medicines, 105 Main St E, Level P1, Hamilton, Ontario, Canada L8N 1G6 (holbrook@mcmaster.ca).

Accepted for Publication: December 21, 2004.

Financial Disclosure: None.

Albers  GWDalen  JELaupacis  AManning  WJPetersen  PSinger  DE Antithrombotic therapy in atrial fibrillation. Chest 2001;119 ((suppl)) 194S- 206S
PubMed Link to Article
Stein  PDAlpert  JSBussey  HIDalen  JETurpie  AGG Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119 ((suppl)) 220S- 227S[published correction appears in Chest. 2001;120:1044]
PubMed Link to Article
Hyers  TMAGHull  RDMorris  TASamama  MTapson  VWeg  JG Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 ((suppl)) 176S- 193S
PubMed Link to Article
Cairns  JATheroux  PLewis  HD  JrEzekowitz  MMeade  TW Antithrombotic agents in coronary artery disease. Chest 2001;119 ((suppl)) 228S- 252S[published correction appears in Chest. 2001;120:1427]
PubMed Link to Article
Hirsh  JDalen  JAnderson  DR  et al.  Oral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range. Chest 2001;119 ((suppl 1)) 8S- 21S
PubMed Link to Article
Wells  PSHolbrook  AMCrowther  NRHirsh  J Interactions of warfarin with drugs and food. Ann Intern Med 1994;121676- 683
PubMed Link to Article
Beyth  RJQuinn  LMLandefeld  CS Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;10591- 99
PubMed Link to Article
Fleiss  JL Statistical Methods for Rates and Proportions.  New York, NY John Wiley & Sons1981;212- 225
Stading  JASkrabal  MZFaulkner  MA Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001;582076- 2080
PubMed
Mersfelder  TLStewart  LR Warfarin and celecoxib interaction. Ann Pharmacother 2000;34325- 327
PubMed Link to Article
Wood  GDDeeble  T Warfarin: dangers with antibiotics. Dent Update 1993;20350- 353
PubMed
Beckey  NPKorman  LBParra  D Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy. Pharmacotherapy 1999;191075- 1079
PubMed Link to Article
Kim  JMWhite  RH Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 1996;77545- 546
PubMed Link to Article
Lidell  CSvedberg  LELindell  PBandh  SJob  BWallentin  L Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost 2003;89842- 846
PubMed
Engelsen  JNielsen  JDHansen  KE Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;1651868- 1871
PubMed
Israel  DSStotka  JRock  W  et al.  Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 1996;22251- 256
PubMed Link to Article
Gebauer  MGNyfort-Handsen  KHenschke  PJGallus  AS Warfarin and acetaminophen interaction. Pharmacotherapy 2003;23109- 112
PubMed Link to Article
Lambert  JCormier  J Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001;21509- 512
PubMed Link to Article
Priskorn  MSidhu  JSLarsen  FDavis  JDKhan  AZRolan  PE Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44199- 202
PubMed Link to Article
Stoysich  AMLucas  BDMohiuddin  SMHilleman  DE Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther 1996;3456- 60
PubMed
Dingemanse  JMeyerhoff  CSchadrack  J Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 2002;53485- 491
PubMed Link to Article
Ascah  KJRock  GAWells  PS Interaction between fenofibrate and warfarin. Ann Pharmacother 1998;32765- 768
PubMed Link to Article
Buckley  MSGoff  ADKnapp  WE Fish oil interaction with warfarin. Ann Pharmacother 2004;3850- 53
PubMed Link to Article
Monterrey-Rodriguez  J Interaction between warfarin and mango fruit [letter]. Ann Pharmacother 2002;36940- 941
PubMed Link to Article
Thirion  DJZanetti  LA Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 2000;2098- 99
PubMed Link to Article
Wong  ALNChan  TYK Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother 2003;37836- 838
PubMed Link to Article
Apseloff  GWilner  KDGerber  NTremaine  LM Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32 ((suppl 1)) 37- 42
PubMed Link to Article
Purkins  LWood  NKleinermans  DNichols  D Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;5624- 29
PubMed Link to Article
Awni  WMHussein  ZGranneman  GRPatterson  KJDube  LMCavanaugh  JH Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet 1995;29 ((suppl 2)) 67- 76
PubMed Link to Article
Ermer  JCHicks  DRWheeler  SCKraml  MJusko  WJ Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. Clin Pharmacol Ther 1994;55305- 316
PubMed Link to Article
Martin  LAMehta  SD Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy 2003;23260- 264
PubMed Link to Article
Marinella  MA Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother 1998;32841- 842
PubMed Link to Article
Schulman  S Inhibition of warfarin activity by ribavirin. Ann Pharmacother 2002;3672- 74
PubMed Link to Article
Small  NLGiamonna  KA Interaction between warfarin and trazodone. Ann Pharmacother 2000;34734- 736
PubMed Link to Article
Yates  RAWong  JSeiberling  MMerz  MMarz  WNauck  M The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001;51429- 435
PubMed Link to Article
Brown  PMHursting  MJ Lack of pharmacokinetic interactions between argatroban and warfarin. Am J Health Syst Pharm 2002;592078- 2083
PubMed
Mallikaarjun  SBramer  SL Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet 1999;37 ((suppl 2)) 79- 86
PubMed Link to Article
Tiseo  PJFoley  KFriedhoff  LT The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46 ((suppl 1)) 45- 50
PubMed Link to Article
Kazierad  DJMartin  DEIlson  B  et al.  Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol 1998;38649- 653
PubMed Link to Article
Faaij  RABurggraaf  JSchoemaker  RCvan Amsterdam  RGMCohen  AF Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol 2002;54304- 308
PubMed Link to Article
Davy  MBird  NRost  KLFuder  H Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy 1999;45491- 495
PubMed Link to Article
Ragueneau-Majlessi  ILevy  RHMeyerhoff  C Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 2001;4755- 63
PubMed Link to Article
Kong  ANTomasko  LWaldman  SA  et al.  Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995;351008- 1015
PubMed Link to Article
Turck  DSu  CAHeinzel  GBusch  UBluhmki  EHoffmann  J Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997;51421- 425
PubMed Link to Article
Heinig  RKitchin  NRolan  P Disposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate. Clin Drug Invest 1999;18151- 159
Link to Article
Schall  RMuller  FOHundt  HKDuursema  LGroenewoud  GMiddle  MV Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung 1996;4641- 46
PubMed
Robertson  P  JrHellriegel  ETArora  SNelson  M Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002;42205- 214
PubMed Link to Article
Van Hecken  AVerbesselt  RDepre  M  et al.  Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993;45291- 293
PubMed Link to Article
Van Hecken  ADepre  MVerbesselt  R  et al.  Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999;39495- 500
PubMed
Anderson  DMShelley  SCrick  NBuraglio  M No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol 2002;421358- 1365
PubMed Link to Article
Salazar  DEDockens  RCMilbrath  RL  et al.  Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35730- 738
PubMed Link to Article
Duursema  LMuller  FOSchall  R  et al.  Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995;39700- 703
PubMed Link to Article
Burke  SAmin  NIncerti  CPlone  MWatson  N Sevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 2001;41193- 198
PubMed Link to Article
Byrd  DCGaskins  SEParrish  AMFreeman  LB Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract 1999;12486- 488
PubMed Link to Article
McMorran  MMorawiecka  I Celecoxib (Celebrex): 1 year later. CMAJ 2000;1621044- 1046, 1048-1050
PubMed
Dent  LAOrrock  MW Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997;17170- 172
PubMed
Guerret  MFrancheteau  PHuber  M Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 1997;17767- 773
PubMed
Warwick  JACorrall  RJ Serious interaction between warfarin and oral terbinafine. BMJ 1998;316440
PubMed Link to Article
Gupta  AKRoss  GS Interaction between terbinafine and warfarin. Dermatology 1998;196266- 267
PubMed Link to Article
Newshan  GTsang  P Ritonavir and warfarin interaction. AIDS 1999;131788- 1789
PubMed Link to Article
Poli  DChiarugi  LCapanni  M  et al.  Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis 2002;13297- 300
PubMed Link to Article
Lipsky  BAPecoraro  RERoben  NJde Blaquiere  PDelaney  CJ Influenza vaccination and warfarin anticoagulation. Ann Intern Med 1984;100835- 837
PubMed Link to Article
Kramer  PTsuru  MCook  CEMcClain  CJHoltzman  JL Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984;35416- 418
PubMed Link to Article
Duursema  LMuller  FOHundt  HKHeyns  ADMeyer  BHLuus  HG Model to detect warfarin-drug interactions in man. Drug Investig 1992;4395- 402
Link to Article
Heimark  LDWienkers  LKunze  K  et al.  The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51398- 407
PubMed Link to Article
Almog  SShafran  NHalkin  H  et al.  Mechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985;28257- 261
PubMed Link to Article
O'Reilly  RATrager  WFRettie  AEGoulart  DA Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987;42290- 294
PubMed Link to Article
Pyorala  KMyllyla  GKekki  M Metabolism of warfarin during methandrostenolone treatment. Ann Med Exp Biol Fenn 1965;4395- 97
PubMed
Lorentz  SMWeibert  RT Potentiation of warfarin anticoagulation by topical testosterone ointment. Clin Pharm 1985;4332- 334
PubMed
Toon  SHopkins  KJGarstang  FMRowland  M Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987;32165- 172
PubMed Link to Article
O'Reilly  RA Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984;144989- 991
PubMed Link to Article
Bell  WRAnderson  KCNoe  DASilver  BA Reduction in the plasma clearance rate of warfarin induced by cimetidine. Arch Intern Med 1986;1462325- 2328
PubMed Link to Article
Serlin  MJSibeon  RGMossman  S  et al.  Cimetidine: interaction with oral anticoagulants in man. Lancet 1979;2317- 319
PubMed Link to Article
Sax  MJRandolph  WCPeace  KE  et al.  Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy. Clin Pharm 1987;6492- 495[published correction appears in Clin Pharm. 1988;7:269]
PubMed
Hunt  BASax  MJChretien  SFrank  WOBraverman  AJ Stereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens. Pharmacotherapy 1989;9184
O'Reilly  RASahud  MARobinson  AJ Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh 1972;27309- 318
PubMed
O'Reilly  RAMotley  CH Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med 1979;9134- 36
PubMed Link to Article
Weibert  RTLorentz  SMTownsend  RJCook  CEKlauber  MRJagger  PI Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989;8210- 214
PubMed
Black  DEvans  JSeaton  TGidal  BMcDonnell  NKunze  K Evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract]. Clin Pharmacol Ther 1992;51piii- 52
Rosenthal  ARSelf  THBaker  EDLinden  RA Interaction of isoniazid and warfarin. JAMA 1977;2382177
PubMed Link to Article
O'Reilly  RA The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295354- 357
PubMed Link to Article
O'Reilly  RAGoulart  DAKunze  KL  et al.  Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992;51656- 667
PubMed Link to Article
Sutfin  TBalmer  KBostrom  HEriksson  SHoglund  PPaulsen  O Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11176- 184
PubMed Link to Article
Aggeler  PMO'Reilly  RALeong  LKowitz  PE Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med 1967;276496- 501
PubMed Link to Article
O'Reilly  RATrager  WFMotley  CHHowald  W Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest 1980;65746- 753
PubMed Link to Article
Rhodes  RSRhodes  PJKlein  CSintek  CD A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm 1985;19556- 558
PubMed
Kates  REYee  YGKirsten  EB Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987;42305- 311
PubMed Link to Article
Scott  AKPark  BKBreckenridge  AM Interaction between warfarin and propranolol. Br J Clin Pharmacol 1984;17 ((suppl 1)) 86S
PubMed Link to Article
Bax  NDLennard  MSTucker  GT  et al.  The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 1984;17 ((suppl 1)) 85S
PubMed Link to Article
Nenci  GGAgnelli  GBerrettini  M Biphasic sulphinpyrazone-warfarin interaction. Br Med J (Clin Res Ed) 1981;2821361- 1362
PubMed Link to Article
O'Reilly  RA Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation 1982;65202- 207
PubMed Link to Article
Toon  SLow  LKGibaldi  M  et al.  The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986;3915- 24
PubMed Link to Article
O'Reilly  RATrager  WFMotley  CHHowald  W Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980;28187- 195
PubMed Link to Article
Orme  MBreckenridge  A Enantiomers of warfarin and phenobarbital. N Engl J Med 1976;2951482- 1483
PubMed
Hansen  JMSiersboek-Nielsen  KSkovsted  L Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971;12539- 543
PubMed
Breckenridge  AOrme  M Clinical implications of enzyme induction. Ann N Y Acad Sci 1971;179421- 430
PubMed Link to Article
Robinson  DSBenjamin  DMMcCormack  JJ Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther 1971;12491- 495
PubMed
Jahnchen  EMeinertz  TGilfrich  HJKersting  FGroth  U Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978;5437- 440
PubMed Link to Article
Okino  KWeibert  RT Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986;20291- 293
PubMed
Cullen  SICatalano  P Griseofulvin-warfarin antagonism. JAMA 1967;199582- 583
PubMed Link to Article
Qureshi  GDReinders  TPSomori  GJEvans  HJ Warfarin resistance with nafcillin therapy. Ann Intern Med 1984;100527- 529
PubMed Link to Article
O'Reilly  RA Interaction of sodium warfarin and rifampin: studies in man. Ann Intern Med 1974;81337- 340
PubMed Link to Article
Heimark  LDGibaldi  MTrager  WFO'Reilly  RAGoulart  DA The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987;42388- 394
PubMed Link to Article
Mungall  DTalbert  RLPhillips  CJaffe  DLudden  TM Sucralfate and warfarin [letter]. Ann Intern Med 1983;98557
PubMed Link to Article
Talbert  RLDalmady-Israel  CBussey  HICrawford  MHLudden  TM Effect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy. Drug Intell Clin Pharm 1985;1959
Qureshi  GDReinders  TPSwint  JJSlate  MB Acquired warfarin resistance and weight-reducing diet. Arch Intern Med 1981;141507- 509
PubMed Link to Article
Parr  MDRecord  KEGriffith  GLZeok  JVTodd  EP Effect of enteral nutrition on warfarin therapy. Clin Pharm 1982;1274- 276
PubMed
Blickstein  DShaklai  MInbal  A Warfarin antagonism by avocado [letter]. Lancet 1991;337914- 915
PubMed Link to Article
O'Reilly  RA Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med 1981;141458- 459
PubMed Link to Article
O'Reilly  RA Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. Am J Med Sci 1979;277189- 194
PubMed Link to Article
Nipper  HKirby  SIber  FL Effect of bumetanide on the serum disappearance of warfarin sodium. J Clin Pharmacol 1981;21654- 656
PubMed Link to Article
Serlin  MJMossman  SSibeon  RGTempero  KFBreckenridge  AM Interaction between diflunisal and warfarin. Clin Pharmacol Ther 1980;28493- 498
PubMed Link to Article
Toon  SHopkins  KJGarstang  FMAarons  LSedman  ARowland  M Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987;4233- 41
PubMed Link to Article
De Lepeleire  IVan Hecken  AVerbesselt  R  et al.  Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res 1990;10167- 171
PubMed
Grind  MMurphy  MWarrington  SAberg  J Method for studying drug-warfarin interactions. Clin Pharmacol Ther 1993;54381- 387
PubMed Link to Article
Rowe  HCarmichael  RLemberger  L The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci 1978;23807- 812
PubMed Link to Article
Toon  SHolt  BLMullins  FGBullingham  RAarons  LRowland  M Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990;30743- 750
PubMed Link to Article
Benedek  IHKing  SYPowell  RJAgra  AMSchary  WLPieniaszek  HJ  Jr Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1992;32558- 563
PubMed Link to Article
Jain  AMcMahon  FGSlattery  JTLevy  G Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther 1979;2561- 66
PubMed
Cournot  ABerlin  ISallord  JCSinglas  E Lack of interaction between nizatidine and warfarin during chronic administration. J Clin Pharmacol 1988;281120- 1122
PubMed Link to Article
Serlin  MJSibeon  RGBreckenridge  AM Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol 1981;12791- 794
PubMed Link to Article
Orme  MBreckenridge  ACook  P Warfarin and distalgesic interaction. BMJ 1976;1200
PubMed Link to Article
Davydov  LYermolnik  MCuni  LJ Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003;37367- 370
PubMed Link to Article
Foster  DRMilan  NL Potential interaction between azithromycin and warfarin. Pharmacotherapy 1999;19902- 908
PubMed Link to Article
Udall  JA Warfarin interactions with chloral hydrate and glutethimide. Curr Ther Res Clin Exp 1975;1767- 74
PubMed
Byers  M Clarithromycin-warfarin interaction resulting in an elevated INR. Can J Hosp Pharm 1997;50285- 287
Izzat  MBYim  APEl Zufari  MH A taste of Chinese medicine. Ann Thorac Surg 1998;66941- 942
PubMed Link to Article
Smith  RPrudden  DHawkes  C Propoxyphene and warfarin interaction [letter]. Drug Intell Clin Pharm 1984;18822
PubMed
O'Reilly  RA Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther 1981;29332- 336
PubMed Link to Article
Page  RLLawrence  JD Potentiation of warfarin by dong quai. Pharmacotherapy 1999;19870- 876
PubMed Link to Article
Carabino  JWang  F International normalized ratio fluctuation with warfarin-fluorouracil therapy [letter]. Am J Health Syst Pharm 2002;59875
PubMed
Trilli  LEKelley  CLAspinall  SLKroner  BA Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996;301399- 1402
PubMed
Limke  KKShelton  ARElliott  ES Fluvoxamine interaction with warfarin. Ann Pharmacother 2002;361890- 1892
PubMed Link to Article
Kinikar  SAKolesar  JM Identification of a gemcitabine-warfarin interaction. Pharmacotherapy 1999;191331- 1333
PubMed Link to Article
Bartle  WR Grapefruit juice might still be factor in warfarin response [letter]. Am J Health Syst Pharm 1999;56676
PubMed
Adachi  YYokoyama  YNanno  TYamamoto  T Potentiation of warfarin by interferon. BMJ 1995;311292
PubMed Link to Article
Yeh  JSoo  SCSummerton  CRichardson  C Potentiation of action of warfarin by itraconazole. BMJ 1990;301669
PubMed Link to Article
Scarfe  MAIsrael  MK Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994;28464- 467
PubMed
Ravnan  SLLocke  C Levofloxacin and warfarin interaction. Pharmacotherapy 2001;21884- 885
PubMed Link to Article
Lam  AYElmer  GWMohutsky  MA Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother 2001;351199- 1201
PubMed Link to Article
Davis  NBNahlik  LVogelzang  NJ Does PC-SPES interact with warfarin? J Urol 2002;1671793
PubMed Link to Article
Thompson  MEHighley  MS Interaction between paclitaxel and warfarin [letter]. Ann Oncol 2003;14500
PubMed Link to Article
Fitzmaurice  DAMurray  JA Potentiation of the anticoagulant effect of warfarin. Postgrad Med J 1997;73439- 440
PubMed Link to Article
Levine  MSheppard  I Biphasic interaction of phenytoin with warfarin. Clin Pharm 1984;3200- 203
PubMed
Koch-Weser  J Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med 1968;68511- 517
PubMed Link to Article
Bair  JDOppelt  TF Warfarin and ropinirole interaction. Ann Pharmacother 2001;351202- 1204
PubMed Link to Article
Gaw  AWosornu  D Simvastatin during warfarin therapy in hyperlipoproteinaemia [letter]. Lancet 1992;340979- 980
PubMed Link to Article
Lin  JCIto  MKStolley  SNMorreale  APMarcus  DB The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 1999;3986- 90
PubMed Link to Article
Lodwick  RMcConkey  BBrown  AM Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed) 1987;2951141
PubMed Link to Article
Westfall  LK An unrecognized cause of warfarin resistance [letter]. Drug Intell Clin Pharm 1981;15131
PubMed
Danos  EA Apparent potentiation of warfarin activity by tetracycline. Clin Pharm 1992;11806- 808
PubMed
Colucci  VJRivey  MP Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;331173- 1176
PubMed Link to Article
Sabbe  JRSims  PJSims  MH Tramadol-warfarin interaction. Pharmacotherapy 1998;18871- 873
PubMed
Scher  MLHuntington  NHVitillo  JA Potential interaction between tramadol and warfarin [letter]. Ann Pharmacother 1997;31646- 647
PubMed
Plowman  BKMorreale  AP Possible troglitazone-warfarin interaction [letter]. Am J Health Syst Pharm 1998;551071
PubMed
Rotenberg  MLevy  YShoenfeld  YAlmog  SEzra  D Effect of azathioprine on the anticoagulant activity of warfarin. Ann Pharmacother 2000;34120- 122
PubMed Link to Article
Murphey  LMHood  EH Bosentan and warfarin interaction. Ann Pharmacother 2003;371028- 1031
PubMed Link to Article
Jonkman  JHvan Lier  JJvan Heiningen  PNLins  RSennewald  RHogemann  A Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997;11 ((suppl 2)) S31- S35
PubMed
Grebe  HBGregory  PJ Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy 2002;221067- 1069
PubMed Link to Article
Krstenansky  PMJones  WNGarewal  HS Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clin Pharm 1987;6804- 806
PubMed
Mailloux  ATGidal  BESorkness  CA Potential interaction between warfarin and dicloxacillin. Ann Pharmacother 1996;301402- 1407
PubMed
Rosado  MF Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology 2003;99111
PubMed Link to Article
Kurnik  DLubetsky  ALoebstein  RAlmog  SHalkin  H Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. Ann Pharmacother 2003;371603- 1606
PubMed Link to Article
Miller  JWSkerjanec  AKnadler  MPGhosh  AAllerheiligen  SRB Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. Pharm Res 2001;181024- 1028
PubMed Link to Article
Knoell  KRYoung  TMCousins  ES Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;321299- 1302
PubMed Link to Article
Cambria-Kiely  JA Effect of soy milk on warfarin efficacy. Ann Pharmacother 2002;361893- 1896
PubMed Link to Article
Stern  RAbel  RGibson  GLBesserer  J Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 1997;371062- 1064
PubMed Link to Article
Kelly  JMurdoch  RDClark  DJWebber  DMFuder  H Warfarin pharmacodynamics unaffected by cilomilast. Ann Pharmacother 2001;351535- 1539
PubMed Link to Article
Donovan  JMStypinski  DStiles  MROlson  TABurke  SK Drug interactions with colesevelam hydrochloride: a novel potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14681- 690
PubMed Link to Article
Schulman  SHenriksson  K Interaction of ibuprofen and warfarin on primary haemostasis. Br J Rheumatol 1989;2846- 49
PubMed Link to Article
Brass  CGalgiani  JNBlaschke  TFDefelice  RO'Reilly  RAStevens  DA Disposition of ketoconazole an oral antifungal in humans. Antimicrob Agents Chemother 1982;21151- 158
PubMed Link to Article
Mieszczak  CWinther  K Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol 1993;44205- 206
PubMed Link to Article
Antila  SJarvinen  AHonkanen  TLehtonen  L Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol 2000;56705- 710
PubMed Link to Article
Morreale  APJanetzky  K Probable interaction of warfarin and acarbose. Am J Health Syst Pharm 1997;541551- 1552
PubMed
Woeber  KAWarner  I Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. West J Med 1999;17049- 51
PubMed
Bandrowsky  TVorono  AABorris  TJMarcantoni  HW Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82610- 612
PubMed Link to Article
Malacarne  PMaestri  A Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter]. Recenti Prog Med 1996;87135
PubMed
Leone  RGhiotto  EConforti  AVelo  G Potential interaction between warfarin and ocular chloramphenicol [letter]. Ann Pharmacother 1999;33114
PubMed Link to Article
Suvarna  RPirmohamed  MHenderson  L Possible interaction between warfarin and cranberry juice. BMJ 2003;3271454
PubMed Link to Article
Yue  QJansson  K Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component [letter]. J Am Geriatr Soc 2001;49838
PubMed Link to Article
Booth  CD Drug interaction between danazol and warfarin. Pharm J 1993;250439- 440
Tam  LSChan  TYLeung  WKCritchley  JA Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter]. Aust N Z J Med 1995;25258
PubMed Link to Article
Sylven  CAnderson  P Evidence that disopyramide does not interact with warfarin. Br Med J (Clin Res Ed) 1983;2861181
PubMed Link to Article
Haworth  EBurroughs  AK Disopyramide and warfarin interaction. BMJ 1977;2866- 867
PubMed Link to Article
Tisdel  KAIsrael  DSKolb  KW Warfarin-felbamate interaction: first report [letter]. Ann Pharmacother 1994;28805
PubMed
Artymowicz  RJCino  BJRossi  JGWalker  JLMoore  S Possible interaction between gatifloxacin and warfarin. Am J Health Syst Pharm 2002;591205- 1206
PubMed
Rindone  JPKeng  HC Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. Chest 1998;114641- 642
PubMed Link to Article
Chan  TYLui  SFChung  SYLuk  SCritchley  JA Adverse interaction between warfarin and indomethacin. Drug Saf 1994;10267- 269
PubMed Link to Article
Hall  GLind  MJHuang  M  et al.  Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. Postgrad Med J 1990;66860- 861
PubMed Link to Article
Ahmad  S Lovastatin: warfarin interaction. Arch Intern Med 1990;1502407
PubMed Link to Article
Lim  VPande  I Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 2002;3251333
PubMed Link to Article
Trewin  VF A probable interaction between warfarin and metolazone. Pharm J 1988;18781- 782
Evans  JOrme  DSSedgwick  MLYoungs  GR Treating oral candidiasis: potentially fatal [letter]. Br Dent J 1997;182452
PubMed Link to Article
Leor  JLevartowsky  DSharon  C Interaction between nalidixic acid and warfarin [letter]. Ann Intern Med 1987;107601
PubMed Link to Article
Linville  TMatanin  D Norfloxacin and warfarin. Ann Intern Med 1989;110751- 752
PubMed Link to Article
Leor  JMatetzki  S Ofloxacin and warfarin [letter]. Ann Intern Med 1988;109761
PubMed Link to Article
Baciewicz  AMAshar  BHLocke  TW Interaction of ofloxacin and warfarin [letter]. Ann Intern Med 1993;1191223
PubMed Link to Article
MacWalter  RSFraser  HWArmstrong  KM Orlistat enhances warfarin effect. Ann Pharmacother 2003;37510- 512
PubMed Link to Article
Littleton  F Warfarin and topical salicylates [letter]. JAMA 1990;2632888
PubMed Link to Article
Chow  WHCheung  KLLing  HMSee  T Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med 1989;82501- 502
PubMed
Darlington  MR Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann Pharmacother 1997;31647
PubMed
Carter  SA Potential effect of sulindac on response of prothrombin-time to oral anticoagulants. Lancet 1979;2698- 699
PubMed Link to Article
Ross  JRBeeley  L Sulindac prothrombin time and anticoagulants [letter]. Lancet 1979;21075
PubMed Link to Article
Gidal  BESorkness  CAMcGill  KALarson  RLevine  RR Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995;1733- 38
PubMed Link to Article
Koren  JFCochran  DLJanes  RL Tolmetin-warfarin interaction. Am J Med 1987;821278- 1280
PubMed Link to Article
Nissenblatt  MJKarp  GI Bleeding risk with trastuzumab (Herceptin) treatment. JAMA 1999;2822299- 2301
PubMed Link to Article
Snyder  DS Interaction between cyclosporine and warfarin [letter]. Ann Intern Med 1988;108311
PubMed Link to Article
Ostlere  LSLangtry  JAJones  SStaughton  RC Reduced therapeutic effect of warfarin caused by etretinate [letter]. Br J Dermatol 1991;124505
PubMed Link to Article
Teefy  AMMartin  JEKovacs  MJ Warfarin resistance due to sulfasalazine. Ann Pharmacother 2000;341265- 1268
PubMed Link to Article
Bartle  WRMadorin  PGuylaine  F Seaweed, vitamin K, and warfarin [letter]. Am J Health Syst Pharm 2001;582300
PubMed
Stangier  JSu  CAHendriks  MG  et al.  Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol 2000;401331- 1337
PubMed
Spigset  O Reduced effect of warfarin caused by ubidecarenone [letter]. Lancet 1994;3441372- 1373
PubMed Link to Article
Beringer  TR Warfarin potentiation with bezafibrate. Postgrad Med J 1997;73657- 658
PubMed Link to Article
Angaran  DMDias  VCArom  KV  et al.  The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: cefamandole cefazolin vancomycin. Ann Surg 1987;206155- 161
PubMed Link to Article
Le  ATHasson  NKLum  BL Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. Ann Pharmacother 1997;311006- 1008
PubMed
Thomas  PFennerty  ABlackhouse  G Oral anticoagulant during treatment with heparin. Br Med J (Clin Res Ed) 1984;288191
PubMed Link to Article
Wehbe  TWWarth  JA A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. Clin Pharmacol Ther 1996;59360- 362
PubMed Link to Article
Ellison  J Apparent interaction between warfarin and levonorgestrel used for emergency contraception. BMJ 2000;3211382
PubMed Link to Article
Kaufman  M Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. Mult Scler 1997;3248- 249
PubMed Link to Article
Dennis  VCThomas  BKHanlon  JE Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone. Pharmacotherapy 2000;20234- 239
PubMed Link to Article
Rogers  Tde Leon  JAtcher  D Possible interaction between warfarin and quetiapine [letter]. J Clin Psychopharmacol 1999;19382- 383
PubMed Link to Article
Sioris  LJWeibert  RTPentel  PR Potentiation of warfarin anticoagulation by sulfisoxazole. Arch Intern Med 1980;140546- 547
PubMed Link to Article
Ibrahim  OMAllam  A Warfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin. Saudi Pharm J 1996;456- 59
Laizure  SCMadlock  LCyr  MSelf  T Decreased hypoprothrombinemic effect of warfarin associated with furosemide. Ther Drug Monit 1997;19361- 363
PubMed Link to Article
Taylor  JRWilt  VM Probable antagonism of warfarin by green tea. Ann Pharmacother 1999;33426- 428
PubMed Link to Article
Setter  SMLawless  KHunter  KA Need for continuity of care in patients receiving warfarin and nafcillin/dicloxacillin. Hosp Pharm 1996;311269- 1271
MacLaren  RWachsman  BASwift  DKKuhl  DA Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy 1997;171331- 1337
PubMed
Agosta  FGLiberato  NLChiofalo  F Warfarin resistance induced by teicoplanin [letter]. Haematologica 1997;82637- 638
PubMed
May  JRDiPiro  JTSisley  JF Drug interactions in surgical patients. Am J Surg 1987;153327- 335
PubMed Link to Article
Gabb  GM Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter]. Med J Aust 1996;164700- 701
PubMed
Baciewicz  AMMenke  JJBokar  JABaud  EB Fluconazole-warfarin interaction [letter]. Ann Pharmacother 1994;281111
PubMed
Haase  KKRojas-Fernandez  CHLane  LFrank  DA Potential interaction between celecoxib and warfarin. Ann Pharmacother 2000;34666- 667
PubMed Link to Article
Janetzky  KMorreale  AP Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997;54692- 693
PubMed
Holbrook  AMWells  PSCrowther  NR Pharmacokinetics and drug interactions with warfarin. Poller  LHirsh  JOral Anticoagulants Dunton Green, England Hodder and Stoughton1996;
Indiana University Department of Medicine Web site, Cytochrome P450 drug interaction table. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed July 15, 2004
O'Reilly  RA Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 1980;30233- 35
PubMed Link to Article
Hirsh  JAnsell  JAnsell  JHalperin  JL American Heart Association/American College of Cardiology foundation guide to warfarin therapy. Circulation 2003;1071692- 1711
PubMed Link to Article
Harris  JE Interaction of dietary factors with oral anticoagulants: review and applications. J Am Diet Assoc 1995;95580- 584
PubMed Link to Article
O'Reilly  RARytand  D “Resistance” to warfarin due to unrecognized vitamin K supplementation [letter]. N Engl J Med 1980;303160- 161
PubMed
Pedersen  FMHamburg  OHess  KOvesen  L The effect of dietary vitamin K on warfarin-induced anticoagulants. J Intern Med 1991;229517- 520
PubMed Link to Article
Owens  JCNeely  JBOwen  WR Effect of sodium dextrothyroxine in patients receiving anticoagulation. N Engl J Med 1962;26676- 79
PubMed Link to Article
Antlitz  AMMead  JA  JrTolentino  MA Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res Clin Exp 1968;10501- 507
PubMed
Hylek  EMHeiman  HSkates  SJSheehan  MASinger  DE Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279657- 662
PubMed Link to Article
Kwan  DBartle  WRWalker  SE The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999;3968- 75
PubMed Link to Article
Gianni  LMDreitlein  WB Some popular OTC herbals can interact with anticoagulant therapy. US Pharm 1998;2380, 83- 84, 86
Joshi  BSKaul  PN Alternative medicine: herbal drugs and their critical appraisal—part I. Prog Drug Res 2001;561- 76
PubMed
Holbrook  AMJanjusevic  VKeshavjee  KLee  HK Measuring quality of prescribing: where does the information reside? [abstract]. Can J Clin Pharmacol 2002;940
Holbrook  AMKeshavjee  KGoldsmith  CHTucker  JPark  L Advancing the measurement of quality of care using electronic medical records. Proc Towards Electron Patient Rec 1999;1848- 855

Figures

Tables

Table Graphic Jump LocationTable 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction*
Table Graphic Jump LocationTable 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug Group

References

Albers  GWDalen  JELaupacis  AManning  WJPetersen  PSinger  DE Antithrombotic therapy in atrial fibrillation. Chest 2001;119 ((suppl)) 194S- 206S
PubMed Link to Article
Stein  PDAlpert  JSBussey  HIDalen  JETurpie  AGG Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119 ((suppl)) 220S- 227S[published correction appears in Chest. 2001;120:1044]
PubMed Link to Article
Hyers  TMAGHull  RDMorris  TASamama  MTapson  VWeg  JG Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119 ((suppl)) 176S- 193S
PubMed Link to Article
Cairns  JATheroux  PLewis  HD  JrEzekowitz  MMeade  TW Antithrombotic agents in coronary artery disease. Chest 2001;119 ((suppl)) 228S- 252S[published correction appears in Chest. 2001;120:1427]
PubMed Link to Article
Hirsh  JDalen  JAnderson  DR  et al.  Oral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range. Chest 2001;119 ((suppl 1)) 8S- 21S
PubMed Link to Article
Wells  PSHolbrook  AMCrowther  NRHirsh  J Interactions of warfarin with drugs and food. Ann Intern Med 1994;121676- 683
PubMed Link to Article
Beyth  RJQuinn  LMLandefeld  CS Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;10591- 99
PubMed Link to Article
Fleiss  JL Statistical Methods for Rates and Proportions.  New York, NY John Wiley & Sons1981;212- 225
Stading  JASkrabal  MZFaulkner  MA Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001;582076- 2080
PubMed
Mersfelder  TLStewart  LR Warfarin and celecoxib interaction. Ann Pharmacother 2000;34325- 327
PubMed Link to Article
Wood  GDDeeble  T Warfarin: dangers with antibiotics. Dent Update 1993;20350- 353
PubMed
Beckey  NPKorman  LBParra  D Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy. Pharmacotherapy 1999;191075- 1079
PubMed Link to Article
Kim  JMWhite  RH Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 1996;77545- 546
PubMed Link to Article
Lidell  CSvedberg  LELindell  PBandh  SJob  BWallentin  L Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. Thromb Haemost 2003;89842- 846
PubMed
Engelsen  JNielsen  JDHansen  KE Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;1651868- 1871
PubMed
Israel  DSStotka  JRock  W  et al.  Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin Infect Dis 1996;22251- 256
PubMed Link to Article
Gebauer  MGNyfort-Handsen  KHenschke  PJGallus  AS Warfarin and acetaminophen interaction. Pharmacotherapy 2003;23109- 112
PubMed Link to Article
Lambert  JCormier  J Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy 2001;21509- 512
PubMed Link to Article
Priskorn  MSidhu  JSLarsen  FDavis  JDKhan  AZRolan  PE Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44199- 202
PubMed Link to Article
Stoysich  AMLucas  BDMohiuddin  SMHilleman  DE Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther 1996;3456- 60
PubMed
Dingemanse  JMeyerhoff  CSchadrack  J Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 2002;53485- 491
PubMed Link to Article
Ascah  KJRock  GAWells  PS Interaction between fenofibrate and warfarin. Ann Pharmacother 1998;32765- 768
PubMed Link to Article
Buckley  MSGoff  ADKnapp  WE Fish oil interaction with warfarin. Ann Pharmacother 2004;3850- 53
PubMed Link to Article
Monterrey-Rodriguez  J Interaction between warfarin and mango fruit [letter]. Ann Pharmacother 2002;36940- 941
PubMed Link to Article
Thirion  DJZanetti  LA Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. Pharmacotherapy 2000;2098- 99
PubMed Link to Article
Wong  ALNChan  TYK Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother 2003;37836- 838
PubMed Link to Article
Apseloff  GWilner  KDGerber  NTremaine  LM Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32 ((suppl 1)) 37- 42
PubMed Link to Article
Purkins  LWood  NKleinermans  DNichols  D Voriconazole potentiates warfarin-induced prothrombin time prolongation. Br J Clin Pharmacol 2003;5624- 29
PubMed Link to Article
Awni  WMHussein  ZGranneman  GRPatterson  KJDube  LMCavanaugh  JH Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin Pharmacokinet 1995;29 ((suppl 2)) 67- 76
PubMed Link to Article
Ermer  JCHicks  DRWheeler  SCKraml  MJusko  WJ Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. Clin Pharmacol Ther 1994;55305- 316
PubMed Link to Article
Martin  LAMehta  SD Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. Pharmacotherapy 2003;23260- 264
PubMed Link to Article
Marinella  MA Mesalamine and warfarin therapy resulting in decreased warfarin effect. Ann Pharmacother 1998;32841- 842
PubMed Link to Article
Schulman  S Inhibition of warfarin activity by ribavirin. Ann Pharmacother 2002;3672- 74
PubMed Link to Article
Small  NLGiamonna  KA Interaction between warfarin and trazodone. Ann Pharmacother 2000;34734- 736
PubMed Link to Article
Yates  RAWong  JSeiberling  MMerz  MMarz  WNauck  M The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001;51429- 435
PubMed Link to Article
Brown  PMHursting  MJ Lack of pharmacokinetic interactions between argatroban and warfarin. Am J Health Syst Pharm 2002;592078- 2083
PubMed
Mallikaarjun  SBramer  SL Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. Clin Pharmacokinet 1999;37 ((suppl 2)) 79- 86
PubMed Link to Article
Tiseo  PJFoley  KFriedhoff  LT The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46 ((suppl 1)) 45- 50
PubMed Link to Article
Kazierad  DJMartin  DEIlson  B  et al.  Eprosartan does not affect the pharmacodynamics of warfarin. J Clin Pharmacol 1998;38649- 653
PubMed Link to Article
Faaij  RABurggraaf  JSchoemaker  RCvan Amsterdam  RGMCohen  AF Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol 2002;54304- 308
PubMed Link to Article
Davy  MBird  NRost  KLFuder  H Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy 1999;45491- 495
PubMed Link to Article
Ragueneau-Majlessi  ILevy  RHMeyerhoff  C Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res 2001;4755- 63
PubMed Link to Article
Kong  ANTomasko  LWaldman  SA  et al.  Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1995;351008- 1015
PubMed Link to Article
Turck  DSu  CAHeinzel  GBusch  UBluhmki  EHoffmann  J Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol 1997;51421- 425
PubMed Link to Article
Heinig  RKitchin  NRolan  P Disposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate. Clin Drug Invest 1999;18151- 159
Link to Article
Schall  RMuller  FOHundt  HKDuursema  LGroenewoud  GMiddle  MV Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung 1996;4641- 46
PubMed
Robertson  P  JrHellriegel  ETArora  SNelson  M Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002;42205- 214
PubMed Link to Article
Van Hecken  AVerbesselt  RDepre  M  et al.  Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993;45291- 293
PubMed Link to Article
Van Hecken  ADepre  MVerbesselt  R  et al.  Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1999;39495- 500
PubMed
Anderson  DMShelley  SCrick  NBuraglio  M No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol 2002;421358- 1365
PubMed Link to Article
Salazar  DEDockens  RCMilbrath  RL  et al.  Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35730- 738
PubMed Link to Article
Duursema  LMuller  FOSchall  R  et al.  Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. Br J Clin Pharmacol 1995;39700- 703
PubMed Link to Article
Burke  SAmin  NIncerti  CPlone  MWatson  N Sevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics. J Clin Pharmacol 2001;41193- 198
PubMed Link to Article
Byrd  DCGaskins  SEParrish  AMFreeman  LB Warfarin and ciprofloxacin interaction: case report and controversy. J Am Board Fam Pract 1999;12486- 488
PubMed Link to Article
McMorran  MMorawiecka  I Celecoxib (Celebrex): 1 year later. CMAJ 2000;1621044- 1046, 1048-1050
PubMed
Dent  LAOrrock  MW Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997;17170- 172
PubMed
Guerret  MFrancheteau  PHuber  M Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. Pharmacotherapy 1997;17767- 773
PubMed
Warwick  JACorrall  RJ Serious interaction between warfarin and oral terbinafine. BMJ 1998;316440
PubMed Link to Article
Gupta  AKRoss  GS Interaction between terbinafine and warfarin. Dermatology 1998;196266- 267
PubMed Link to Article
Newshan  GTsang  P Ritonavir and warfarin interaction. AIDS 1999;131788- 1789
PubMed Link to Article
Poli  DChiarugi  LCapanni  M  et al.  Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis 2002;13297- 300
PubMed Link to Article
Lipsky  BAPecoraro  RERoben  NJde Blaquiere  PDelaney  CJ Influenza vaccination and warfarin anticoagulation. Ann Intern Med 1984;100835- 837
PubMed Link to Article
Kramer  PTsuru  MCook  CEMcClain  CJHoltzman  JL Effect of influenza vaccine on warfarin anticoagulation. Clin Pharmacol Ther 1984;35416- 418
PubMed Link to Article
Duursema  LMuller  FOHundt  HKHeyns  ADMeyer  BHLuus  HG Model to detect warfarin-drug interactions in man. Drug Investig 1992;4395- 402
Link to Article
Heimark  LDWienkers  LKunze  K  et al.  The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51398- 407
PubMed Link to Article
Almog  SShafran  NHalkin  H  et al.  Mechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination. Eur J Clin Pharmacol 1985;28257- 261
PubMed Link to Article
O'Reilly  RATrager  WFRettie  AEGoulart  DA Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. Clin Pharmacol Ther 1987;42290- 294
PubMed Link to Article
Pyorala  KMyllyla  GKekki  M Metabolism of warfarin during methandrostenolone treatment. Ann Med Exp Biol Fenn 1965;4395- 97
PubMed
Lorentz  SMWeibert  RT Potentiation of warfarin anticoagulation by topical testosterone ointment. Clin Pharm 1985;4332- 334
PubMed
Toon  SHopkins  KJGarstang  FMRowland  M Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol 1987;32165- 172
PubMed Link to Article
O'Reilly  RA Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Arch Intern Med 1984;144989- 991
PubMed Link to Article
Bell  WRAnderson  KCNoe  DASilver  BA Reduction in the plasma clearance rate of warfarin induced by cimetidine. Arch Intern Med 1986;1462325- 2328
PubMed Link to Article
Serlin  MJSibeon  RGMossman  S  et al.  Cimetidine: interaction with oral anticoagulants in man. Lancet 1979;2317- 319
PubMed Link to Article
Sax  MJRandolph  WCPeace  KE  et al.  Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy. Clin Pharm 1987;6492- 495[published correction appears in Clin Pharm. 1988;7:269]
PubMed
Hunt  BASax  MJChretien  SFrank  WOBraverman  AJ Stereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens. Pharmacotherapy 1989;9184
O'Reilly  RASahud  MARobinson  AJ Studies on the interaction of warfarin and clofibrate in man. Thromb Diath Haemorrh 1972;27309- 318
PubMed
O'Reilly  RAMotley  CH Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med 1979;9134- 36
PubMed Link to Article
Weibert  RTLorentz  SMTownsend  RJCook  CEKlauber  MRJagger  PI Effect of erythromycin in patients receiving long-term warfarin therapy. Clin Pharm 1989;8210- 214
PubMed
Black  DEvans  JSeaton  TGidal  BMcDonnell  NKunze  K Evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract]. Clin Pharmacol Ther 1992;51piii- 52
Rosenthal  ARSelf  THBaker  EDLinden  RA Interaction of isoniazid and warfarin. JAMA 1977;2382177
PubMed Link to Article
O'Reilly  RA The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976;295354- 357
PubMed Link to Article
O'Reilly  RAGoulart  DAKunze  KL  et al.  Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin Pharmacol Ther 1992;51656- 667
PubMed Link to Article
Sutfin  TBalmer  KBostrom  HEriksson  SHoglund  PPaulsen  O Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11176- 184
PubMed Link to Article
Aggeler  PMO'Reilly  RALeong  LKowitz  PE Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med 1967;276496- 501
PubMed Link to Article
O'Reilly  RATrager  WFMotley  CHHowald  W Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest 1980;65746- 753
PubMed Link to Article
Rhodes  RSRhodes  PJKlein  CSintek  CD A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm 1985;19556- 558
PubMed
Kates  REYee  YGKirsten  EB Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987;42305- 311
PubMed Link to Article
Scott  AKPark  BKBreckenridge  AM Interaction between warfarin and propranolol. Br J Clin Pharmacol 1984;17 ((suppl 1)) 86S
PubMed Link to Article
Bax  NDLennard  MSTucker  GT  et al.  The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol 1984;17 ((suppl 1)) 85S
PubMed Link to Article
Nenci  GGAgnelli  GBerrettini  M Biphasic sulphinpyrazone-warfarin interaction. Br Med J (Clin Res Ed) 1981;2821361- 1362
PubMed Link to Article
O'Reilly  RA Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation 1982;65202- 207
PubMed Link to Article
Toon  SLow  LKGibaldi  M  et al.  The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 1986;3915- 24
PubMed Link to Article
O'Reilly  RATrager  WFMotley  CHHowald  W Interaction of secobarbital with warfarin pseudoracemates. Clin Pharmacol Ther 1980;28187- 195
PubMed Link to Article
Orme  MBreckenridge  A Enantiomers of warfarin and phenobarbital. N Engl J Med 1976;2951482- 1483
PubMed
Hansen  JMSiersboek-Nielsen  KSkovsted  L Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clin Pharmacol Ther 1971;12539- 543
PubMed
Breckenridge  AOrme  M Clinical implications of enzyme induction. Ann N Y Acad Sci 1971;179421- 430
PubMed Link to Article
Robinson  DSBenjamin  DMMcCormack  JJ Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther 1971;12491- 495
PubMed
Jahnchen  EMeinertz  TGilfrich  HJKersting  FGroth  U Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol 1978;5437- 440
PubMed Link to Article
Okino  KWeibert  RT Warfarin-griseofulvin interaction. Drug Intell Clin Pharm 1986;20291- 293
PubMed
Cullen  SICatalano  P Griseofulvin-warfarin antagonism. JAMA 1967;199582- 583
PubMed Link to Article
Qureshi  GDReinders  TPSomori  GJEvans  HJ Warfarin resistance with nafcillin therapy. Ann Intern Med 1984;100527- 529
PubMed Link to Article
O'Reilly  RA Interaction of sodium warfarin and rifampin: studies in man. Ann Intern Med 1974;81337- 340
PubMed Link to Article
Heimark  LDGibaldi  MTrager  WFO'Reilly  RAGoulart  DA The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther 1987;42388- 394
PubMed Link to Article
Mungall  DTalbert  RLPhillips  CJaffe  DLudden  TM Sucralfate and warfarin [letter]. Ann Intern Med 1983;98557
PubMed Link to Article
Talbert  RLDalmady-Israel  CBussey  HICrawford  MHLudden  TM Effect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy. Drug Intell Clin Pharm 1985;1959
Qureshi  GDReinders  TPSwint  JJSlate  MB Acquired warfarin resistance and weight-reducing diet. Arch Intern Med 1981;141507- 509
PubMed Link to Article
Parr  MDRecord  KEGriffith  GLZeok  JVTodd  EP Effect of enteral nutrition on warfarin therapy. Clin Pharm 1982;1274- 276
PubMed
Blickstein  DShaklai  MInbal  A Warfarin antagonism by avocado [letter]. Lancet 1991;337914- 915
PubMed Link to Article
O'Reilly  RA Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. Arch Intern Med 1981;141458- 459
PubMed Link to Article
O'Reilly  RA Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. Am J Med Sci 1979;277189- 194
PubMed Link to Article
Nipper  HKirby  SIber  FL Effect of bumetanide on the serum disappearance of warfarin sodium. J Clin Pharmacol 1981;21654- 656
PubMed Link to Article
Serlin  MJMossman  SSibeon  RGTempero  KFBreckenridge  AM Interaction between diflunisal and warfarin. Clin Pharmacol Ther 1980;28493- 498
PubMed Link to Article
Toon  SHopkins  KJGarstang  FMAarons  LSedman  ARowland  M Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. Clin Pharmacol Ther 1987;4233- 41
PubMed Link to Article
De Lepeleire  IVan Hecken  AVerbesselt  R  et al.  Lack of interaction between famotidine and warfarin. Int J Clin Pharmacol Res 1990;10167- 171
PubMed
Grind  MMurphy  MWarrington  SAberg  J Method for studying drug-warfarin interactions. Clin Pharmacol Ther 1993;54381- 387
PubMed Link to Article
Rowe  HCarmichael  RLemberger  L The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci 1978;23807- 812
PubMed Link to Article
Toon  SHolt  BLMullins  FGBullingham  RAarons  LRowland  M Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1990;30743- 750
PubMed Link to Article
Benedek  IHKing  SYPowell  RJAgra  AMSchary  WLPieniaszek  HJ  Jr Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol 1992;32558- 563
PubMed Link to Article
Jain  AMcMahon  FGSlattery  JTLevy  G Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. Clin Pharmacol Ther 1979;2561- 66
PubMed
Cournot  ABerlin  ISallord  JCSinglas  E Lack of interaction between nizatidine and warfarin during chronic administration. J Clin Pharmacol 1988;281120- 1122
PubMed Link to Article
Serlin  MJSibeon  RGBreckenridge  AM Lack of effect of ranitidine on warfarin action. Br J Clin Pharmacol 1981;12791- 794
PubMed Link to Article
Orme  MBreckenridge  ACook  P Warfarin and distalgesic interaction. BMJ 1976;1200
PubMed Link to Article
Davydov  LYermolnik  MCuni  LJ Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 2003;37367- 370
PubMed Link to Article
Foster  DRMilan  NL Potential interaction between azithromycin and warfarin. Pharmacotherapy 1999;19902- 908
PubMed Link to Article
Udall  JA Warfarin interactions with chloral hydrate and glutethimide. Curr Ther Res Clin Exp 1975;1767- 74
PubMed
Byers  M Clarithromycin-warfarin interaction resulting in an elevated INR. Can J Hosp Pharm 1997;50285- 287
Izzat  MBYim  APEl Zufari  MH A taste of Chinese medicine. Ann Thorac Surg 1998;66941- 942
PubMed Link to Article
Smith  RPrudden  DHawkes  C Propoxyphene and warfarin interaction [letter]. Drug Intell Clin Pharm 1984;18822
PubMed
O'Reilly  RA Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. Clin Pharmacol Ther 1981;29332- 336
PubMed Link to Article
Page  RLLawrence  JD Potentiation of warfarin by dong quai. Pharmacotherapy 1999;19870- 876
PubMed Link to Article
Carabino  JWang  F International normalized ratio fluctuation with warfarin-fluorouracil therapy [letter]. Am J Health Syst Pharm 2002;59875
PubMed
Trilli  LEKelley  CLAspinall  SLKroner  BA Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996;301399- 1402
PubMed
Limke  KKShelton  ARElliott  ES Fluvoxamine interaction with warfarin. Ann Pharmacother 2002;361890- 1892
PubMed Link to Article
Kinikar  SAKolesar  JM Identification of a gemcitabine-warfarin interaction. Pharmacotherapy 1999;191331- 1333
PubMed Link to Article
Bartle  WR Grapefruit juice might still be factor in warfarin response [letter]. Am J Health Syst Pharm 1999;56676
PubMed
Adachi  YYokoyama  YNanno  TYamamoto  T Potentiation of warfarin by interferon. BMJ 1995;311292
PubMed Link to Article
Yeh  JSoo  SCSummerton  CRichardson  C Potentiation of action of warfarin by itraconazole. BMJ 1990;301669
PubMed Link to Article
Scarfe  MAIsrael  MK Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother 1994;28464- 467
PubMed
Ravnan  SLLocke  C Levofloxacin and warfarin interaction. Pharmacotherapy 2001;21884- 885
PubMed Link to Article
Lam  AYElmer  GWMohutsky  MA Possible interaction between warfarin and Lycium barbarum L. Ann Pharmacother 2001;351199- 1201
PubMed Link to Article
Davis  NBNahlik  LVogelzang  NJ Does PC-SPES interact with warfarin? J Urol 2002;1671793
PubMed Link to Article
Thompson  MEHighley  MS Interaction between paclitaxel and warfarin [letter]. Ann Oncol 2003;14500
PubMed Link to Article
Fitzmaurice  DAMurray  JA Potentiation of the anticoagulant effect of warfarin. Postgrad Med J 1997;73439- 440
PubMed Link to Article
Levine  MSheppard  I Biphasic interaction of phenytoin with warfarin. Clin Pharm 1984;3200- 203
PubMed
Koch-Weser  J Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. Ann Intern Med 1968;68511- 517
PubMed Link to Article
Bair  JDOppelt  TF Warfarin and ropinirole interaction. Ann Pharmacother 2001;351202- 1204
PubMed Link to Article
Gaw  AWosornu  D Simvastatin during warfarin therapy in hyperlipoproteinaemia [letter]. Lancet 1992;340979- 980
PubMed Link to Article
Lin  JCIto  MKStolley  SNMorreale  APMarcus  DB The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 1999;3986- 90
PubMed Link to Article
Lodwick  RMcConkey  BBrown  AM Life threatening interaction between tamoxifen and warfarin. Br Med J (Clin Res Ed) 1987;2951141
PubMed Link to Article
Westfall  LK An unrecognized cause of warfarin resistance [letter]. Drug Intell Clin Pharm 1981;15131
PubMed
Danos  EA Apparent potentiation of warfarin activity by tetracycline. Clin Pharm 1992;11806- 808
PubMed
Colucci  VJRivey  MP Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;331173- 1176
PubMed Link to Article
Sabbe  JRSims  PJSims  MH Tramadol-warfarin interaction. Pharmacotherapy 1998;18871- 873
PubMed
Scher  MLHuntington  NHVitillo  JA Potential interaction between tramadol and warfarin [letter]. Ann Pharmacother 1997;31646- 647
PubMed
Plowman  BKMorreale  AP Possible troglitazone-warfarin interaction [letter]. Am J Health Syst Pharm 1998;551071
PubMed
Rotenberg  MLevy  YShoenfeld  YAlmog  SEzra  D Effect of azathioprine on the anticoagulant activity of warfarin. Ann Pharmacother 2000;34120- 122
PubMed Link to Article
Murphey  LMHood  EH Bosentan and warfarin interaction. Ann Pharmacother 2003;371028- 1031
PubMed Link to Article
Jonkman  JHvan Lier  JJvan Heiningen  PNLins  RSennewald  RHogemann  A Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens 1997;11 ((suppl 2)) S31- S35
PubMed
Grebe  HBGregory  PJ Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy 2002;221067- 1069
PubMed